JP2020505044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505044A5 JP2020505044A5 JP2019540095A JP2019540095A JP2020505044A5 JP 2020505044 A5 JP2020505044 A5 JP 2020505044A5 JP 2019540095 A JP2019540095 A JP 2019540095A JP 2019540095 A JP2019540095 A JP 2019540095A JP 2020505044 A5 JP2020505044 A5 JP 2020505044A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- genetically modified
- protein
- composition
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022173206A JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762450917P | 2017-01-26 | 2017-01-26 | |
| US62/450,917 | 2017-01-26 | ||
| PCT/US2018/015180 WO2018140573A1 (en) | 2017-01-26 | 2018-01-25 | B-cell engineering |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173206A Division JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505044A JP2020505044A (ja) | 2020-02-20 |
| JP2020505044A5 true JP2020505044A5 (enExample) | 2020-12-17 |
Family
ID=62979713
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540095A Withdrawn JP2020505044A (ja) | 2017-01-26 | 2018-01-25 | Ｂ細胞操作 |
| JP2022173206A Pending JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173206A Pending JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190352614A1 (enExample) |
| EP (1) | EP3573464A4 (enExample) |
| JP (2) | JP2020505044A (enExample) |
| KR (1) | KR20190111063A (enExample) |
| CN (1) | CN110536963A (enExample) |
| AU (1) | AU2018212652B2 (enExample) |
| BR (1) | BR112019015355A2 (enExample) |
| CA (1) | CA3051113A1 (enExample) |
| IL (1) | IL268110B2 (enExample) |
| MX (1) | MX2019008844A (enExample) |
| WO (1) | WO2018140573A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| CN110536963A (zh) * | 2017-01-26 | 2019-12-03 | 桑格摩生物治疗股份有限公司 | B细胞工程改造 |
| AU2018235957B2 (en) | 2017-03-16 | 2024-02-01 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins |
| JP2021507561A (ja) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． | 音響トランスデューサドライバ及びコントローラ |
| EP3867380A2 (en) | 2018-10-18 | 2021-08-25 | Intellia Therapeutics, Inc. | Compositions and methods for expressing factor ix |
| EP4070855B1 (en) | 2019-11-01 | 2025-12-24 | Kyoto Prefectural Public University Corporation | B-cell antibody receptor and use thereof |
| EP4127188A4 (en) | 2020-03-31 | 2024-08-21 | Walking Fish Therapeutics | MODIFIED B CELLS AND METHODS OF USE THEREOF |
| US20260048123A1 (en) * | 2022-03-30 | 2026-02-19 | Fred Hutchinson Cancer Center | Systems and methods to produce b cells that express selected antibodies and gene products |
| WO2024151683A2 (en) * | 2023-01-09 | 2024-07-18 | Walking Fish Therapeutics, Inc. | HUMAN B CELL ENGINEERED TO EXPRESS IgA AND IgM ANTIBODIES FOR THERAPEUTIC USE |
| WO2024196669A2 (en) * | 2023-03-17 | 2024-09-26 | Walking Fish Therapeutics, Inc. | Methods for in vivo editing of b cells |
| EP4698191A2 (en) * | 2023-04-17 | 2026-02-25 | Be Biopharma, Inc. | Engineered cell preparations for treatment of niemann pick b disease |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003901511A0 (en) * | 2003-03-28 | 2003-04-17 | Bionomics Limited | Nucleic acid molecules associated with angiogenesis II |
| ES2436741T3 (es) * | 2004-09-22 | 2014-01-07 | St. Jude Children's Research Hospital | Expresión mejorada de Factor IX en vectores de terapia génica |
| JP6215533B2 (ja) * | 2009-04-09 | 2017-10-18 | サンガモ セラピューティクス， インコーポレイテッド | 幹細胞への標的組込み |
| CN116083487A (zh) * | 2013-05-15 | 2023-05-09 | 桑格摩生物治疗股份有限公司 | 用于治疗遗传病状的方法和组合物 |
| US9757420B2 (en) * | 2014-07-25 | 2017-09-12 | Sangamo Therapeutics, Inc. | Gene editing for HIV gene therapy |
| CN113699113A (zh) * | 2014-09-16 | 2021-11-26 | 桑格摩治疗股份有限公司 | 用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物 |
| EP3234107B1 (en) * | 2014-12-19 | 2022-09-14 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents |
| ES2959608T3 (es) * | 2015-04-03 | 2024-02-27 | Dana Farber Cancer Inst Inc | Composición y métodos de edición del genoma de células B |
| PE20181090A1 (es) * | 2015-06-24 | 2018-07-09 | Janssen Biotech Inc | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 |
| AU2016291778B2 (en) * | 2015-07-13 | 2021-05-06 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| ES2895430T3 (es) * | 2016-01-15 | 2022-02-21 | Univ Minnesota | Métodos y composiciones para el tratamiento de enfermedad neurológica |
| CN110536963A (zh) * | 2017-01-26 | 2019-12-03 | 桑格摩生物治疗股份有限公司 | B细胞工程改造 |
| CR20190509A (es) * | 2017-04-10 | 2020-01-08 | Immatics Biotechnologies Gmbh | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer |
| EP3638783A4 (en) * | 2017-06-16 | 2021-03-10 | Sangamo Therapeutics, Inc. | TARGETED T-LYMPHOCYTE AND / OR HLA RECEPTOR INTERRUPTION |
| WO2019032675A1 (en) * | 2017-08-08 | 2019-02-14 | Sangamo Therapeutics, Inc. | CELL TARGETING MEDIATED BY A CHIMERIC ANTIGEN RECEPTOR |
| JP2021502085A (ja) * | 2017-11-09 | 2021-01-28 | サンガモ セラピューティクス， インコーポレイテッド | サイトカイン誘導性ｓｈ２含有タンパク質（ｃｉｓｈ）遺伝子の遺伝子改変 |
| US20230158070A1 (en) * | 2018-01-30 | 2023-05-25 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen |
| AU2019327913A1 (en) * | 2018-08-29 | 2021-03-18 | Nanjing Legend Biotech Co., Ltd. | Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof |
| EP3887395A4 (en) * | 2018-11-30 | 2022-07-27 | Intima Bioscience, Inc. | METHODS FOR IDENTIFICATION OF IMMUNOMODULATORY GENES |
-
2018
- 2018-01-25 CN CN201880021264.1A patent/CN110536963A/zh active Pending
- 2018-01-25 CA CA3051113A patent/CA3051113A1/en active Pending
- 2018-01-25 US US16/480,939 patent/US20190352614A1/en not_active Abandoned
- 2018-01-25 KR KR1020197023790A patent/KR20190111063A/ko not_active Ceased
- 2018-01-25 BR BR112019015355A patent/BR112019015355A2/pt not_active IP Right Cessation
- 2018-01-25 JP JP2019540095A patent/JP2020505044A/ja not_active Withdrawn
- 2018-01-25 EP EP18744407.0A patent/EP3573464A4/en not_active Withdrawn
- 2018-01-25 WO PCT/US2018/015180 patent/WO2018140573A1/en not_active Ceased
- 2018-01-25 IL IL268110A patent/IL268110B2/en unknown
- 2018-01-25 AU AU2018212652A patent/AU2018212652B2/en not_active Ceased
- 2018-01-25 MX MX2019008844A patent/MX2019008844A/es unknown
-
2022
- 2022-10-28 JP JP2022173206A patent/JP2022191524A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505044A5 (enExample) | ||
| Wienert et al. | Wake-up sleepy gene: reactivating fetal globin for β-hemoglobinopathies | |
| Staal et al. | Autologous stem-cell-based gene therapy for inherited disorders: state of the art and perspectives | |
| JP2017500061A5 (enExample) | ||
| Xi et al. | Genetically engineered pigs for xenotransplantation: Hopes and challenges | |
| Hudecek et al. | Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side | |
| JP2020500162A5 (enExample) | ||
| JP2016539627A5 (enExample) | ||
| Amelio et al. | p63 the guardian of human reproduction | |
| Kohn | Gene therapy for blood diseases | |
| JP2017504354A5 (enExample) | ||
| US12385070B2 (en) | Homology directed repair compositions for the treatment of hemoglobinopathies | |
| Paladini et al. | The multifaceted nature of aminopeptidases ERAP1, ERAP2, and LNPEP: from evolution to disease | |
| Naeimi Kararoudi et al. | Clustered regularly interspaced short palindromic repeats/Cas9 gene editing technique in xenotransplantation | |
| Bueren et al. | Advances in the gene therapy of monogenic blood cell diseases | |
| Shi et al. | Platelets as delivery systems for disease treatments | |
| ES3032739T3 (en) | Genetically engineered hematopoietic stem cell as a platform for systemic protein expression | |
| Patel et al. | The immune response to the fVIII gene therapy in preclinical models | |
| Crossley et al. | Effective therapies for sickle cell disease: are we there yet? | |
| Ly et al. | Gene therapy in the treatment of heart failure | |
| EP3765617A1 (en) | Systems and methods for the treatment of hemoglobinopathies | |
| Bottino et al. | Use of genetically-engineered pig donors in islet transplantation | |
| Březina et al. | Mechanisms of direct and indirect presentation of self-antigens in the thymus | |
| Naldini et al. | The EHA research roadmap: hematopoietic stem cell gene therapy | |
| Barbarani et al. | β-Hemoglobinopathies: the test bench for genome editing-based therapeutic strategies |